Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust grew its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 37.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,347 shares of the company's stock after purchasing an additional 42,734 shares during the quarter. Emerald Mutual Fund Advisers Trust owned about 0.38% of Keros Therapeutics worth $2,459,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. AlphaQuest LLC lifted its position in Keros Therapeutics by 469.0% during the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock worth $57,000 after buying an additional 2,964 shares in the last quarter. Virtus ETF Advisers LLC raised its holdings in shares of Keros Therapeutics by 107.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock worth $61,000 after acquiring an additional 1,998 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of Keros Therapeutics during the 4th quarter valued at about $90,000. Exchange Traded Concepts LLC acquired a new position in shares of Keros Therapeutics during the 4th quarter valued at about $99,000. Finally, CANADA LIFE ASSURANCE Co grew its holdings in shares of Keros Therapeutics by 207.8% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company's stock valued at $116,000 after purchasing an additional 4,976 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the acquisition, the insider now directly owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. This trade represents a 27.01 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 22.90% of the company's stock.

Keros Therapeutics Trading Up 0.5 %

KROS traded up $0.08 on Friday, hitting $14.65. 651,753 shares of the company were exchanged, compared to its average volume of 811,465. The firm has a 50-day moving average price of $11.92 and a two-hundred day moving average price of $25.83. Keros Therapeutics, Inc. has a twelve month low of $9.12 and a twelve month high of $72.37. The company has a market cap of $594.95 million, a price-to-earnings ratio of -2.81 and a beta of 1.32.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. Equities analysts expect that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Wedbush reiterated a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a report on Tuesday, April 1st. Oppenheimer lowered their price objective on Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a research report on Thursday, January 16th. Guggenheim reissued a "neutral" rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Scotiabank decreased their price target on Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a research note on Thursday, January 16th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $40.33.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.